Interested In Buying BioNTech SE (BNTX)? Make Sure You Read This First

The stock of BioNTech SE (NASDAQ:BNTX) decreased by decreased by -$8.02 on Friday to finish at $278.34, down -2.80 percent. The last five days have seen an average of 2,802,600 shares of common stock traded. 42 times new highs were reached in the current year, with a gain of $196.82. The average number of shares traded over the last 20 days was 2,814,560, while the average volume over the last 50 days totaled 3,343,118.

BNTX stock dropped -21.15% since last month. On 10/01/21, the company’s shares reached a one-month low of $230.03. The stock touched a high of $464.00 on 08/10/21, after rallying from a low of $75.35 in 52 weeks. The price of BNTX stock has risen by 241.44% or $196.82 this year, reaching a new high 42 times. Still, the stock price is down -40.01% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Valuation Metrics

BioNTech SE (BNTX) has a trailing price-to-earnings (P/E) ratio of 14.65. This level actually compares favorably with the industry at large, as the PE for the Biotechnology industry stands at about 53.59. Further, its PE also compares favorably with the Healthcare sector’s trailing 12 months PE ratio, which comes in at 33.43 right now. The PE ratio of BioNTech SE has varied between 749.25 and 10.77 in the last five years. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 7.69, the price-to-book (PB) ratio of 10.66.

For the three months ended June 29, BioNTech SE’s quick ratio was 2.60, while its current ratio was 2.70, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.09, and the total debt to equity ratio is 0.22. As far as profitability goes, gross margin for the trailing twelve months is 85.00% percent. BioNTech SE’s EBITDA margin for the year ended June 29 was -47.24%, whereas its operating margin stood at 76.20% for the same period. Based on annual data, it had gross profit of $483.18 million and revenue of $550.96 million.

Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. BNTX’s return on assets (ROA) during the last 12 months has been 95.10%. There was a 4.90% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 158.10%. ROE has averaged -68.79 in the past year for the broader industry.

Earnings Surprise

According to BioNTech SE’s quarterly financial report for the quarter that ended June 29, it had $0.63 million in total debt versus $1.01 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $540.2 million, while revenues rose by 77.49% to $0.0. It was predicted that BioNTech SE’s quarterly earnings would be $12.72, but it ended up being $8.95, beating the consensus by 42.10%. EBITDA was $5.08 billion for the quarter. At the end of BioNTech SE’s most recent quarter ended June 29, its liabilities totaled 4.42 billion, while its total debt was $256.8 million.

Technical Picture

Here’s a quick look at BioNTech SE’s (BNTX) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 56.53%, suggesting the stock is Neutral, with a 41.09% historical volatility rate.

The stochastic %K and %D were 82.53% and 74.77% respectively, while the average true range (ATR) was 16.89. Based on the 14-day stochastic reading of 72.59%, the RSI (14) reading is 49.45%. On the 9-day MACD Oscillator, the stock is at 17.01, and the 14-day reading is at 22.97.

Analyst Ratings

In its analyst report released on October 22, 2021, Deutsche Bank began covering BioNTech SE (NASDAQ: BNTX). The stock was rated as a Hold by the brokerage firm. Analysts have assigned BioNTech SE (BNTX) an Hold rating. BNTX is a stock that is recommended for selling by 1 brokerage firm, while 9 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 0 rates it overweight and 4 others recommend it as a buy.

What is BNTX’s price target for the next 12 months?

The current consensus forecast for the stock is between $130.36 and $381.21, with a median target price of $283.90. In analyzing these forecasts, the average price target given by analysts for BioNTech SE (BNTX) is $271.90.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam